JB Chemicals Q4 Review - Ebitda Margin Sustenance Key: Dolat Capital

Pills is shown at a pharmacy. (Photographer: JB Reed/Bloomberg News)

JB Chemicals Q4 Review - Ebitda Margin Sustenance Key: Dolat Capital

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

JB Chemicals and Pharmaceuticals Ltd. reported an in-line Q4. Revenue growth of 19% YoY was driven by both domestic and exports.

With on ground expenses normalising, Ebitda margins stand at 23.4% for Q4 versus 28.6% in nine months-FY21.

One-time income of Rs 198 million (sale of land) aided profit after tax at Rs 1 billion, adjusting for which profit after tax has been in line at Rs 800 million.

India (grew 9% YoY), exports (both formulations and active pharmaceutical ingredient) reported healthy growth at 33% YoY.

Sequentially the growth was muted on a high base.

Management expects India growth led by deeper penetration of legacy portfolio, new launches in chronic segment coupled with productivity improvement.

Click on the attachment to read the full report:

Dolat Capital JB Chemicals & Pharma Q4FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.